Karyopharm Therapeutics (KPTI) Prices 6.25M Share Common Offering at $24/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Barclays Starts Karyopharm Therapeutics (KPTI) at Overweight
March 4, 2020 4:41 AM ESTBarclays analyst Peter Lawson initiates coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with a Overweight rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.
Shares of Karyopharm Therapeutics closed at $24.68 yesterday.
... MorePre-Open Stock Movers 03/03: (MITO) (INO) (WIFI) Higher; (CODX) (TLRY) (KPTI) Lower (more...)
March 3, 2020 9:24 AM ESTToday's Pre-Open Stock Movers
Stealth BioTherapeutics (NASDAQ: MITO) 52.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.
Co-Diagnostics (NASDAQ: CODX) 20.3% LOWER; Maxim Group downgraded from Buy to Hold. Coronavirus plays lower.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) 19.4% HIGHER; announced an accelerated timeline for developing its DNA vaccine... More
After-Hours Stock Movers 03/02: (GNW) (IBIO) (GNMK) Higher; (TLRY) (KPTI) (MAXR) Lower (more...)
March 2, 2020 5:58 PM ESTToday's After-Hours Stock Movers
Genworth Financial, Inc. (NYSE: GNW) 16.3% HIGHER; and China Oceanwide Holdings Group Co., Ltd. (Oceanwide) today announced that they have agreed in principle with the New York State Department of Financial Services (NYDFS) on conditions that are expected to facilitate a reapproval by the NYDFS of the proposed acquisition of control by Oceanwide of Genworth's New York-domiciled insurance company, Genworth Life Insurance Company of New York (GLICNY). Genworth has agreed, among other things, to contribute $100 million to GLICNY at the closing of the Oceanwide... More
Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock
March 2, 2020 4:17 PM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to... More
Karyopharm Therapeutics (KPTI) PT Raised to $37 at RBC Capital
March 2, 2020 1:12 PM ESTRBC Capital analyst Brian Abrahams raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $37.00 (from $26.00) while maintaining an Outperform rating.
removing Speculative Risk qualifieradd'l $500M+ out-year sales oppty in earlier-line MM following this morning's positive BOSTON data.... MoreKaryopharm Therapeutics (KPTI) PT Raised to $43 at H.C. Wainwright
March 2, 2020 12:13 PM ESTH.C. Wainwright analyst Edward White raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $43.00 (from $40.00) while maintaining a Buy rating.
... MorePre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
March 2, 2020 9:24 AM ESTToday's Pre-Open Stock Movers
Forty Seven, Inc. (Nasdaq: FTSV) 62% HIGHER; Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory... More
Karyopharm Therapeutics (KPTI) PT Raised to $35 at Baird
March 2, 2020 8:29 AM ESTBaird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $35.00 (from $25.00) while maintaining an Outperform rating following better-than-expected BOSTON study data.
The analyst commented, "This morning, Karyopharm announced highly anticipated Phase 3 results from the BOSTON study of... More
Karyopharm Therapeutics (KPTI) Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in PFS in Patients with Multiple Myeloma
March 2, 2020 7:01 AM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS). The median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in... More
